CSAG has projected strong revenue growth while concurrently reducing marketing costs (as a percentage of revenue) over the next ten years. It is unreasonable to expect Cellestis to achieve strong revenue growth without a proportionate increase in marketing costs.As it happens Cellestis did provide reasons why CSAG was being reasonable
